Osemitamab Biosimilar – Anti-CLDN18 mAb – Research Grade

Introduction to Osemitamab Biosimilar – Anti-CLDN18 mAb – Research Grade

Osemitamab Biosimilar, also known as Anti-CLDN18 mAb, is a novel therapeutic antibody targeting the Claudin 18.2 (CLDN18.2) protein. It is a research grade biosimilar of the original Osemitamab, which is a fully humanized monoclonal antibody developed by Merus N.V. for the treatment of solid tumors.

Structure of Osemitamab Biosimilar

Osemitamab Biosimilar is a monoclonal antibody (mAb) with a molecular weight of approximately 150 kDa. It is composed of two identical heavy chains and two identical light chains, each containing a variable region and a constant region. The variable region is responsible for binding to the target protein, while the constant region determines the antibody’s effector functions.

Osemitamab Biosimilar is produced using recombinant DNA technology, where the gene encoding for the antibody is inserted into a host cell, usually Chinese hamster ovary (CHO) cells, to produce large quantities of the antibody.

Mechanism of Action

The therapeutic target of Osemitamab Biosimilar is the CLDN18.2 protein, which is overexpressed in many solid tumors, including gastric, pancreatic, and lung cancers. CLDN18.2 is a tight junction protein that plays a crucial role in maintaining the integrity of epithelial tissues. It is also involved in tumor cell proliferation, migration, and invasion.

Osemitamab Biosimilar binds to the extracellular domain of CLDN18.2, leading to the internalization and degradation of the protein. This results in the disruption of tight junctions and subsequent inhibition of tumor growth and metastasis.

Application of Osemitamab Biosimilar

Osemitamab Biosimilar is currently being investigated in clinical trials for the treatment of solid tumors. In a phase I study, Osemitamab showed promising results in patients with advanced gastric or gastroesophageal junction (GEJ) cancer who had previously received chemotherapy. It also demonstrated a manageable safety profile.

Based on these results, a phase II study is currently ongoing to evaluate the efficacy and safety of Osemitamab Biosimilar in combination with chemotherapy in patients with advanced gastric or GEJ cancer. The study aims to assess the overall response rate, progression-free survival, and overall survival of patients treated with Osemitamab Biosimilar.

Moreover, Osemitamab Biosimilar is also being investigated in combination with other treatments, such as immune checkpoint inhibitors, to enhance its anti-tumor activity.

Conclusion

In summary, Osemitamab Biosimilar is a research grade monoclonal antibody that targets the CLDN18.2 protein, which is overexpressed in various solid tumors. Its mechanism of action involves disrupting tight junctions and inhibiting tumor growth and metastasis. Osemitamab Biosimilar is currently being investigated in clinical trials for the treatment of advanced gastric and GEJ cancer, with promising results. Further studies are ongoing to explore its potential in combination with other treatments.